Ravidasvir

DRUG4 trials

Sponsors

Ascletis Pharmaceuticals Co., Ltd.

Conditions

Chronic Hepatitis CHCVHealthy

Phase 1

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

CompletedNCT03020134

Ascletis Pharmaceuticals Co., Ltd.Healthy

Start: 2016-07-15End: 2016-08-22Updated: 2018-06-29

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

CompletedNCT03288636

Ascletis Pharmaceuticals Co., Ltd.HCV

Start: 2017-08-08End: 2017-10-28Updated: 2018-01-17

Phase 2

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

CompletedNCT03020095

Ascletis Pharmaceuticals Co., Ltd.Chronic Hepatitis C

Start: 2015-08-31End: 2017-02-28Updated: 2020-10-22

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

CompletedNCT03362814

Ascletis Pharmaceuticals Co., Ltd.HCV

Start: 2017-07-01End: 2019-04-24Updated: 2020-07-28

Related Papers

Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.

2021-07-122 citations

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China

Journal of Clinical and Translational Hepatology2019-09-2816 citations

Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.

2018-03-1210 citations